{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:42:01Z","timestamp":1777902121352,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Chunghwa Yuming Healthcare Co., Taiwan"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Science Progress"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effectiveness, safety, and cost outcomes of brand-name febuxostat (feburic) and generic febuxostat (feuri) in patients with hyperuricemia or gout in a real-world clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using electronic medical records from Taichung Veterans General Hospital between November 2021 and December 2023. Adult patients with hyperuricemia or gout who initiated febuxostat therapy and had no prior urate-lowering treatment in the preceding 3 months were included. Serum uric acid levels were assessed at baseline, 3 months, and the final follow-up. Propensity score matching (1:1) was applied to balance baseline demographic, clinical, laboratory, cardiovascular, and renal characteristics. Clinical outcomes, laboratory parameters, and medication costs were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both feuri and feburic were associated with significant reductions in serum uric acid levels after 3 months of treatment. At the 3-month assessment, the mean serum uric acid level was modestly lower in the feuri group (5.41\u2009\u00b1\u20092.06\u2005mg\/dL) than in the feburic group (5.75\u2009\u00b1\u20092.12\u2005mg\/dL;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.001). At the final follow-up, serum uric acid levels remained numerically lower in the feuri group, although the difference was not statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.07). The feuri group was prescribed a lower final daily dose, which was associated with lower annual medication costs. The proportions of patients achieving recommended uric acid goals were similar between groups, suggesting broadly comparable clinical effectiveness in routine practice. After propensity score matching (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009486 pairs), no significant differences were observed between groups in cardiovascular, renal, or overall safety outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study suggests that generic febuxostat is associated with safety outcomes comparable to those of the brand-name formulation and may be prescribed at lower doses and lower medication costs in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00368504261433091","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:12:45Z","timestamp":1773252765000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world retrospective cohort study comparing brand-name febuxostat (feburic) and generic febuxostat (feuri)"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-0587","authenticated-orcid":false,"given":"Shang-Feng","family":"Tsai","sequence":"first","affiliation":[{"name":"Taichung Veterans General Hospital"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan"},{"name":"Department of Life Science, Tunghai University, Taichung, Taiwan"},{"name":"Clinical Informatics Division, Department of Digital Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Ju","family":"Wu","sequence":"additional","affiliation":[{"name":"Taichung Veterans General Hospital"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hsu","family":"Chen","sequence":"additional","affiliation":[{"name":"Taichung Veterans General Hospital"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan"},{"name":"Department of Life Science, Tunghai University, Taichung, Taiwan"},{"name":"Ph.D. Program in Tissue Engineering and Regenerative Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee E","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 2403\u20132406.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_3_2","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population","volume":"31","author":"Wallace KL","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582\u20131587.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9501"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42266"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.04.006"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.08.036"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.209"},{"key":"e_1_3_4_9_2","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko TM","year":"2015","unstructured":"Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. Br Med J 2015; 351: h4848. 20150923.","journal-title":"Br Med J"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_3_4_12_2","unstructured":"Food and Administration D. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. Food and Drug Administration 2003."},{"key":"e_1_3_4_13_2","volume-title":"FDA Bioequivalence Standards","author":"Lawrence X","year":"2014","unstructured":"Lawrence X, Yu BVL. FDA Bioequivalence Standards. New York, NY: Springer, 2014."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077545"},{"key":"e_1_3_4_15_2","unstructured":"Center for Drug Evaluation T. Technical Dossier Evaluation on Drugs (2024 accessed February 2 2024 2024)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2017.11.001"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_4_18_2","unstructured":"Administration NHI. Ministry of Welfare and Health. Febuxostat reimbursement coverage No 1030050946. 2014."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.1003"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221504"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037081"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000282"},{"key":"e_1_3_4_23_2","unstructured":"(EMA). EMA. Adenuric EPAR https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adenuric (2008 accessed 21 April 2008)."},{"key":"e_1_3_4_24_2","unstructured":"Pharmacists. DcASoH-S. Febuxostat Monograph for Professionals https:\/\/www.drugs.com\/monograph\/febuxostat.html (2009)."}],"container-title":["Science Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261433091","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00368504261433091","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261433091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:20:24Z","timestamp":1777634424000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00368504261433091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/00368504261433091"],"URL":"https:\/\/doi.org\/10.1177\/00368504261433091","relation":{},"ISSN":["0036-8504","2047-7163"],"issn-type":[{"value":"0036-8504","type":"print"},{"value":"2047-7163","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"00368504261433091"}}